Current research and treatment for epithelial ovarian cancer: A Position Paper from the Helene Harris Memorial Trust

European Journal of Cancer

Volumn 39, Issue 13, 2003, Pages 1818-1827

  Balkwill, F ^a   Bast Jr , R C ^c   Berek, J ^c   Chenevix Trench, G ^c   Gore, M ^c   Hamilton, T ^c   Jacobs, I ^c   Mills, G ^c   Souhami, R ^c   Urban, N ^c   Ursulic, S ^c   Smyth, J ^b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c NONE

Author keywords

Early detection; International collaboration; New targets; Oeromic profiling; Ovarian cancer; Transcriptional profiling

Indexed keywords

AMMINEDICHLORO(2 METHYLPYRIDINE)PLATINUM; ANGIOGENESIS INHIBITOR; CARBOPLATIN; CARBOXYLIC ACID DERIVATIVE; CHEMOKINE; CHEMOKINE RECEPTOR; CISPLATIN; CYCLOBUTANE; CYTOKINE; CYTOKINE ANTIBODY; EPOTHILONE B; EPOTHILONE DERIVATIVE; GEFITINIB; GELATINASE A; GELATINASE B; GROWTH FACTOR; IXABEPILONE; LURTOTECAN; LYSOPHOSPHATIDIC ACID; MATRIX METALLOPROTEINASE INHIBITOR; MITOMYCIN; OXALIPLATIN; PACLITAXEL; PLATINUM; PROTEIN P53; TAXANE DERIVATIVE; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ARTICLE; BENIGN TUMOR; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER MODEL; CANCER RESEARCH; CANCER RISK; CANCER THERAPY; CHEMICAL MODIFICATION; CHROMOSOME ABERRATION; CLINICAL TRIAL; COMPARATIVE GENOMIC HYBRIDIZATION; CYTOTOXICITY; DIARRHEA; DRUG RESPONSE; DRUG SENSITIVITY; DRUG TARGETING; EARLY DIAGNOSIS; EPITHELIUM; GENE EXPRESSION; GENE MUTATION; GENETIC CODE; GENETIC DISORDER; GENETIC TRANSCRIPTION; GENOME; HETEROZYGOSITY LOSS; HUMAN; IMMUNE RESPONSE; LABORATORY; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR BIOLOGY; MOLECULAR GENETICS; NEUROPATHY; NONHEMATOLOGICAL TOXICITY; NONHUMAN; ONCOGENE H RAS; ONCOGENE K RAS; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEOMICS; SIDE EFFECT; SIGNAL TRANSDUCTION; TRANSGENICS; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; FEMALE; FORECASTING; GENETICS; IMMUNOTHERAPY; METHODOLOGY; MUTATION; OVARY TUMOR; RANDOMIZED CONTROLLED TRIAL;

ANTINEOPLASTIC AGENTS; FEMALE; FORECASTING; GENE EXPRESSION; GENES, BRCA1; GENES, BRCA2; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOTHERAPY; MUTATION; OVARIAN NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; TUMOR MARKERS, BIOLOGICAL;

EID: 0142089884     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(03)00511-2     Document Type: Article

References (50)

1. Bayani J., Brenton J.D., Macgregor P.F.et al. Parallel analysis of sporadic primary ovarian carcinomas by spectral karyotyping, comparative genomic hybridization, and expression microarrays. Cancer Res. 62:2002;3466-3476.
2. Gray J.W., Suzuki S., Kuo W.L.et al. Specific keynote. genome copy number abnormalities in ovarian cancer Gynecol. Oncol. 88:2003;S16-21,S22-4.
3. Shi H., Wei S.H., Leu Y.-W.et al. Triple analysis of the cancer epigenome. an integrated microarray system for assessing gene expression, DNA methylation, and histone acetylation Cancer Res. 63:2003;2164-2171.
4. Sridhar S., Ali A.A., Liang Y., El Etreby M.F., Lewis R.W., Kumar M.V. Differential expression of members of the tumor necrosis factor a-related apoptosis-inducing ligand pathway in prostate cancer cells. Cancer Res. 61:2001;7179-7183.
5. Petricoin III E.F., Ardekani A.M., Hitt B.A.et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet. 359:2002;572-577.
6. Dyck H.G., Hamilton T.C., Godwin A.K., Lynch H.T., Maines-Bandiera S., Auersperg N. Autonomy of the epithelial phenotype in human ovarian surface epithelium. changes with neoplastic progression and with a family history of ovarian cancer Int. J. Cancer. 69:1996;429-436.
7. Barakat R.R., Sabbatini P., Bhaskaran D.et al. Intraperitoneal chemotherapy for ovarian carcinoma. results of long-term follow-up Clin. Oncol. 20:2002;694-698.
8. Werness B.A., Ramus S.J., Whittemore A.S.et al. Histopathology of familial ovarian tumors in women from families with and without germline BRCA1 mutations. Hum. Pathol. 31:2000;1420-1424.
9. Thomas N.A., Neville P.J., Baxter S.W., Campbell I.G. Genetic analysis of benign ovarian tumors. Int. J. Cancer. 105:2003;499-505.
10. Denison S.R., Becker N.A., Ferber M.J.et al. Transcriptional profiling reveals that several common fragile-site genes are downregulated in ovarian cancer. Genes, Chromosomes Cancer. 34:2002;406-415.
11. Paige A.J.W., Taylor K.J., Taylor C.et al. WWOX. a candidate tumor suppressor gene involved in multiple tumor types PNAS. 98:2001;11417-11422.
12. Sellar G.C., Watt K.P., Rabiasz G.J.et al. The IgLON family member OPCML (OBCAM) at 11q25 is epigenetically inactivated and demonstrates tumor suppressor function in epithelial ovarian cancer. Nat Genet. 2003.
13. Tutt A.N.J., van Oostrom C.T.M., Ross G.M., van Steeg H., Ashworth A. Disruption of Brca2 increases the spontaneous mutation rate in vivo. synergism with ionizing radiation EMBO Rep. 3:2002;255-260.
14. Shridhar V., Lee J., Pandita A.et al. Genetic analysis of early versus late-stage ovarian tumours 1. Cancer Res. 61:2001;5895-5904.
15. Lu K.H., Patterson A., Atkinson E.N.et al. Selection of potential markers for epithelial ovarian cancer with gene expression array analysis and recursive descent partition analysis. Proc Am Assoc Cancer Res. 44:2003;573.
16. Testa J.R., Getts L.A., Salazar H.et al. Spontaneous transformation of rat ovarian surface epithelial cells results in well to poorly differentiated tumors with a parallel range of cytogenetic complexity. Cancer Res. 54:1994;2778-2784.
17. Roby K.F., Taylor C.C., Sweetwood J.P.et al. Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis. 21:2000;585-591.
18. Auersperg N., Siemens C.H., Myrdal S.E. Human ovarian surface epithelium in primary culture. In Vitro. 20:1984;743-755.
19. Liu J., Yang J.A., Thompson N.et al. Malignant transformation of human ovarian surface epithelial cell through genetic modifications. Proc. Am. Assoc. Cancer Res. 43:2002;23.
20. Liu J., Patterson A., Thompson J.A., Mills G., Gray J., Bast R.C. Jr. Transformation targets of human ovarian surface epithelial cells by oncogenic H-rasV12 or K-ras V12 revealed by gene expression array analysis. Proc. Am. Assoc. Cancer Res. 44:2003;270.
21. Orsulic S., Li Y., Soslow R.A., Vitale-Cross L.A., Gutkind J.S., Varmus H.E. Induction of ovarian cancer by defined multiple genetic changes in a mouse model system. Cancer Cell. 1:2002;53-62.
22. Orsulic S. An RCAS-TVA-based approach to designer mouse models. Mammalian Genome. 13:2002;543-547.
23. Connolly D.C., Bao R., Nitkin A.Y.et al. Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer. Cancer Res. 636:2003;1389-1397.
24. Garofalo A, Naumova E, Manenti L, et al. The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growth orthotopically. Clin Cancer Res [in press].
25. Balkwill F. Chemokine biology in cancer. Semin Immunol. 15:2003;49-55.
26. Scotton C., Milliken D., Wilson J., Raju S., Balkwill F. Analysis of CC chemokine and chemokine receptor expression in solid ovarian tumours. Br. J. Cancer. 85:2001;891-897.
27. Scotton C.J., Wilson J.L., Scott K.et al. Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res. 62:2002;5930-5938.
28. Hu Y.-L., Tee M.-K., Goetzl E.J.et al. Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. J. Natl. Cancer Inst. 93:2001;762-768.
29. Markman M, Liu PY, Wilczynski S, et al. Phase 3 randomized trial of 12 versus 3 months single agent paclitaxel in patients with advanced ovarian cancer who attained clinically-defined complete response to platinum/paclitaxel- based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group Trial. J Clin Oncol [in press].
30. Wall L, Burke F, Barton C, Smyth J, Balkwill F. Interferon gamma induces apoptosis in ovarian cancer cells in vivo and in vitro. Clin Cancer Res [in press].
31. Szlosarek P, Balkwill F. Tumour necrosis factor-a: a potential target in the therapy of solid tumors. Lancet Oncol [in press].
32. Bowman A., Gabra H., Langdon S.P.et al. CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer. identification of an endocrine-sensitive subgroup Clin. Cancer Res. 8:2002;2233-2239.
33. Drucker, B.J., Marincola, F.M., Siao, D.Y., Donlon, T.A., Bangs, C.D., Holder, W.D., A new human pancreatic carcinoma cell line developed for adoptive immunotherapy studies with lymphokine-activated killer cells in nude mice, In Vitro Cell Dev. Biol. 24, 1988, 1179-1187.
34. Verweij J, van Oostrom A, Blay J-Y et al., Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target: results from an EORTC soft tissue and bone sarcoma group phase II study. Eur J Cancer [In press].
35. Disis M.L., Gooley T.A., Rinn K.et al. Generation of T cell immunity to the HER-2/neu protein after active immunization with a HER-2/;neu peptide based vaccine. J. Clin. Oncol. 20:2002;2624-2632.
36. Knutson K.L., Disis M.L. Expansion of HER-2/neu specific T cells ex vivo following immunization with a HER-2/neu peptide based vaccine. Clin. Breast Cancer. 2:2001;73-79.
37. Knutson K.L., Disis M.L. Diversity of the T cell population responding to a dominant HLA-A2 epitope of HER-2/neu in an ovarian cancer patient. Human Immunol. 63:2002;547-557.
38. Chang K., Pastan I. Molecular cloning of messothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. PNAS. 93:1996;136-140.
39. Yousef G.M., Diamandis E.P. The new human tissue kallikrein gene family. structure, function, and association to disease Endocrine Rev. 22:2001;184-204.
40. Diamandis E.P., Yousef G.M. Human tissue kallkreins. a family of new cancer biomarkers Clin. Chem. 48:2002;1198-1205.
41. Kim J.-H., Skates S.J., Uede T.et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA. 287:2002;1671-1679.
42. Pepe MS, Longton G, Anderson G, Schummer M. Selecting differentially expressed genes from microarray experiments. Biometrics [in press].
43. Schummer M., Ng W.G., Bumgarner R.E.et al. Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes expressed in ovarian carcinomas. Gene. 238:1999;375-385.
44. Scholler N., Fu N., Yang Y.et al. Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. PNAS. 96:1999;11531-11536.
45. Skates S.J., Xu F.J., Yu J.H.et al. Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer. 76:1995;2004-2010.
46. Skates S, Pauler DK. Screening based on risk of cancer calculation from Bayesian hierarchical change-point models of longitudinal markers. JASA [in press].
47. McIntosh M.W., Urban N. A parametric empirical bayes method for cancer screening using longitudinal observations of a biomarker. Biostatistics. 2003:2003;27-40.
48. Zhang Z., Barnhill S.D., Zhang H.et al. Combination of multiple serum markers using an artificial neural network to improve specificity in discriminating malignant from benign pelvic masses. Gynecol. Oncol. 73:1999;56-61.
49. McIntosh M.W., Pepe M. Combining several screening tests. optimality of the risk score Biometrics. 58:2002;657-664.
50. Chang K., Pastan I., Willingham M.C. Isolation and characterization of a monoclonal antibody K1, reactive with ovarian cancers and normal mesothelium. Int. J. Cancer. 50:1992;373-381.